Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this study is to evaluate how patients use and engage with a game-based mobile application that is designed to treat opioid use disorder.
Description: Evaluate the number of active sessions per week between PEAR-008 and reSET-O
Measure: Evaluate Participant Engagement Data Time: From Week 1 to Week 8 (End of Treatment)Description: Evaluate if PEAR-008 increases retention in treatment compared to reSET-O by comparing drop-out rates
Measure: Evaluate Treatment Retention Based on Drop-Out Rates Time: Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8 (End of Treatment), Week 12 (Follow-up)Description: Evaluate if PEAR-008 increases abstinence compared to reSET-O, as measured by saliva drug screens, urine drug screens and self-reporting
Measure: Evaluate Illicit Drug Abstinence Time: Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8 (End of Treatment), Week 12 (Follow-up)Description: Evaluate participants' digital therapeutic use patterns based on usage data collected, comparing PEAR-008 to reSET-O
Measure: Evaluate Digital Therapeutic Use Patterns Based on Usage Data Time: From Week 1 to Week 8 (End of Treatment)Description: Assess the effect of PEAR-008 and reSET-O on depressive symptoms using the eight-item Patient Health Questionnaire (PHQ-8) scores from Baseline to End of Treatment and Follow-up. The PHQ's total score ranges from 0 (not clinically significant) to 24 (clinically significant)
Measure: Assess Effect on Depressive Symptoms Time: Baseline, Week 4, Week 8 (End of Treatment), Week 12 (Follow-up)Description: Assess the effect of PEAR-008 and reSET-O on anxiety symptoms using the Generalized Anxiety Disorder-7's (GAD-7) scores from Baseline to End of Treatment and Follow-up. The GAD-7's total score ranges from 0 (not clinically significant) to 21 (clinically significant)
Measure: Assess Effect on Anxiety Symptoms Time: Baseline, Week 4, Week 8 (End of Treatment), Week 12 (Follow-up)Description: Assess the effect of PEAR-008 and reSET-O on recovery capital using the ten-item Brief Assessment of Recovery Capital (BARC-10) scores from Baseline to End of Treatment and Follow-up. The BARC-10's total score ranges from 10 to 60
Measure: Assess Effect on Recovery Capital Time: Baseline, Week 4, Week 8 (End of Treatment), Week 12 (Follow-up)Description: Summarize participant satisfaction surveys and evaluate if PEAR-008 increases participant satisfaction in treatment compared to reSET-O through descriptive statistics
Measure: Describe Participant Satisfaction Surveys Time: Baseline, Week 4, Week 8 (End of Treatment)Description: Summarize participant satisfaction interviews and evaluate if PEAR-008 increases participant satisfaction in treatment compared to reSET-O through descriptive statistics
Measure: Describe Participant Satisfaction Interviews Time: Week 12 (Follow-up)Description: Assess the impact of the COVID-19 pandemic on participants using the five-item Council on American-Islamic Relations (CAIR) Pandemic Impact Questionnaire (C-PIQ) scores from Baseline to End of Treatment and Follow-up. The C-PIQ's total score ranges from 0 to 20
Measure: Assess Coronavirus Disease (COVID-19) Impact Time: Baseline, Week 4, Week 8 (End of Treatment), Week 12 (Follow-up)Description: Assess the effect of the COVID-19 pandemic on depressive symptoms using the COPE: Coronavirus Perinatal Experiences - Impact Survey (COPE-IS) (MODIFIED) scores from Baseline to End of Treatment and Follow-up. Participants will be asked how they are coping with stress during COVID-19 from a list of responses. There is no scoring for this measure
Measure: Assess Coronavirus Disease (COVID-19) Impact on Stress Time: Baseline, Week 4, Week 8 (End of Treatment), Week 12 (Follow-up)Description: Evaluate the correlation between engagement (daily and weekly participant use patterns of PEAR-008 and reSET-O) and treatment outcomes (abstinence and retention in treatment)
Measure: Evaluate Engagement and Efficacy Relationship Time: From Week 1 to Week 8 (End of Treatment), Week 12 (Follow-up)Description: Assess the effect of PEAR-008 and reSET-O on changes in skill acquisition using the Cognitive-Behavioral Therapy Skills Questionnaire (CBTSQ) from Baseline to End of Treatment. The CBTSQ measures two factors: Behavioral Activation (BA) and Cognitive Restructuring (CR). BA factor scores range from 0 to 35, and higher scores indicate greater use of BA skills. CR factor scores range from 0 to 45, and higher scores indicate greater use of CR skills
Measure: Change in Skill Acquisition Time: Baseline, Week 4, Week 8 (End of Treatment), Week 12 (Follow-up)Description: Assess the effect of PEAR-008 and reSET-O on medication adherence rates using findings from saliva drug screens and urine drug screens
Measure: Medication Adherence Rates Time: Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8 (End of Treatment), Week 12 (Follow-up)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports